title: The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate.
abstract: A key hallmark of many aggressive cancers is accelerated glucose metabolism. The enzymes that catalyze the first step of glucose metabolism are hexokinases. High levels of hexokinase 2 (HK2) are found in cancer cells, but only in a limited number of normal tissues. Metabolic reprogramming of cancer cells using the energy blocker, 3-bromopyruvate (3-BP) that inhibits HK2 has the potential to provide tumor-specific anticancer agents. However, the unique structural and functional characteristics of mitochondria prohibit selective subcellular targeting of 3-BP to modulate the function of this organelle for therapeutic gain. A mitochondria targeted gold nanoparticle (T-3-BP-AuNP) decorated with 3-BP and delocalized lipophilic triphenylphosphonium cations to target the mitochondrial membrane potential (Δψm) was developed for delivery of 3-BP to cancer cell mitochondria by taking advantage of higher Δψmin cancer cells compared to normal cells.In vitrostudies demonstrated enhanced anticancer activity of T-3-BP-AuNPs compared to the non-targeted construct NT-3-BP-AuNP or free 3-BP. The anticancer activity of T-3-BP-AuNP was further enhanced upon laser irradiation by exciting the surface plasmon resonance band of AuNP and thereby utilizing a combination of 3-BP chemotherapeutic and AuNP photothermal effects. The less toxic behavior of T-3-BPNPs in normal mesenchymal stem cells indicated that these NPs preferentially kill cancer cells. T-3-BP-AuNPs showed enhanced ability to modulate cancer cell metabolism by inhibiting glycolysis as well as demolishing mitochondrial oxidative phosphorylation. Our findings demonstrated that concerted chemo-photothermal treatment of glycolytic cancer cells with a single NP capable of targeting mitochondria mediating simultaneous release of a glycolytic inhibitor and photothermal ablation may have promise as a new anticancer therapy.
authors.affiliation: NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602.
authors.forename: Sean
authors.initials: S
authors.lastname: Marrache
authors.affiliation: NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602 ; Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602 ; Regenerative Bioscience Center, University of Georgia, 425 River Road, Athens, GA 30602.
authors.forename: Shanta
authors.initials: S
authors.lastname: Dhar